Reirradiation to the pelvis for recurrent rectal cancer

Objectives This study investigated late toxicity and infield progression‐free survival in patients with locally recurrent rectal cancer (LRRC) who had previously received irradiation to the pelvis. Methods Twenty‐two patients were treated by reirradiation to the pelvis between January 2000 and Augus...

Full description

Saved in:
Bibliographic Details
Published in:Journal of surgical oncology 2012-06, Vol.105 (7), p.637-642
Main Authors: Koom, Woong Sub, Choi, Yunseon, Shim, Su Jung, Cha, Jihye, Seong, Jinsil, Kim, Nam Kyu, Nam, Ki Chang, Keum, Ki Chang
Format: Article
Language:English
Subjects:
acute toxicity
Adult
Female
Humans
infield control
late toxicity
Male
Middle Aged
Neoplasm Recurrence, Local - mortality
Neoplasm Recurrence, Local - radiotherapy
Pelvis - radiation effects
Radiotherapy - adverse effects
Rectal Neoplasms - mortality
Rectal Neoplasms - radiotherapy
recurrent rectal cancer
reirradiation
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives This study investigated late toxicity and infield progression‐free survival in patients with locally recurrent rectal cancer (LRRC) who had previously received irradiation to the pelvis. Methods Twenty‐two patients were treated by reirradiation to the pelvis between January 2000 and August 2007. All patients received curative surgery with preoperative or postoperative chemoradiotherapy as an initial treatment. Five patients (23%) underwent surgical resection after reirradiation. The median follow‐up duration was 20 months (range, 7–91 months). Results Two patients (9%) had grade‐3 acute toxicity and eight patients (36%) had grade‐3 to ‐4 late toxicity. The incidence of grade‐3 to ‐4 late toxicity in the gastrointestinal and urinary system was 18% and 27%, respectively. Recurrent tumor location (axial or anterior) and surgical resection after reirradiation significantly influenced severe late toxicity (P = 0.024 and P = 0.039, respectively). In the 17 patients not undergoing surgery after reirradiation, median infield progression‐free survival was 16 months. Reirradiation doses exceeding 50 Gyαβ10 (equivalent dose in 2 Gy fractions) significantly increased the infield progression‐free survival (P = 0.005). Conclusions Tumor location (axial or anterior) and surgery after reirradiation may increase severe late toxicity. In addition, an EQD2 exceeding 50 Gyαβ10 may improve infield control. J. Surg. Oncol. 2012; 105:637–642. © 2011 Wiley Periodicals, Inc.
ISSN:0022-4790
1096-9098
DOI:10.1002/jso.23023